Ipsen News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

16.10.17	Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma (Businesswire)
11.10.17	IPSEN: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
19.09.17	Ipsen Receives Approval from European Commission for Xermelo® (Telotristat Ethyl) for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy (Businesswire)
18.09.17	U.S. FDA Approves New Indication for Ipsen's Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome (Businesswire)
12.09.17	IPSEN: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
10.09.17	Ipsen and Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 (Businesswire)
08.09.17	Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx® (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults (Businesswire)
04.09.17	Ipsen Announces 16 Abstract Presentations of Oncology Portfolio at European Society of Medical Oncology Congress (Businesswire)
15.08.17	IPSEN: Disclosure of Transactions in Own Shares between 07/08/2017 and 11/08/2017 (Businesswire)
11.08.17	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
08.08.17	IPSEN: Disclosure of transactions in own shares between 31/07/2017 and 04/08/2017 (Businesswire)
01.08.17	IPSEN: Disclosure of Transactions in Own Shares Between 24/07/2017 and 28/07/2017 (Businesswire)
25.07.17	IPSEN: Disclosure of transactions in own shares between 17/07/2017 and 21/07/2017 (Businesswire)
18.07.17	IPSEN: Disclosure of transactions in own shares between 10/07/2017 and 14/07/2017 (Businesswire)
18.07.17	Half-year IPSEN liquidity contract statement entered into with NATIXIS (Businesswire)
03.07.17	Ipsen: Somatuline® Autogel® 120 mg Receives Japanese Approval for a New Indication for the Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors (Businesswire)
16.06.17	Ipsen Announces FDA Approval of Dysport® (Abobotulinumtoxina) for the Treatment of Lower Limb Spasticity in Adults (Businesswire)
08.06.17	Ipsen initiates share buy-back program to cover its free performance share allocation plan (Businesswire)
01.06.17	IPSEN: Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to the approval of the Combined Shareholders’ Meeting to be held on 7 June 2017 (Businesswire)
14.04.17	Ipsen Appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer (Businesswire)
10.03.17	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
02.03.17	Ipsen Appoints Benoit Hennion as Executive Vice President and President, Primary Care (Businesswire)
10.01.17	IPSEN: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
21.12.16	Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada (Businesswire)
13.12.16	Ipsen Announces Its Corporate Agenda for 2017 (Businesswire)
09.12.16	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
22.11.16	IPSEN: Disclosure of transactions in own shares between 14/11/2016 and 18/11/2016 (Businesswire)
15.11.16	IPSEN: Disclosure of Transactions in Own Shares between 07/11/2016 and 11/11/2016 (Businesswire)
10.11.16	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
08.11.16	IPSEN: Disclosure of Transactions in Own Shares between 31/10/2016 and 04/11/2016 (Businesswire)
01.11.16	IPSEN: Disclosure of Transactions in Own Shares between 10/24/2016 and 10/28/2016 (Businesswire)
26.10.16	Ipsen Reports 12.2%1 Sales Growth for the Third Quarter of 2016 and Raises Full Year Guidance (Businesswire)
25.10.16	IPSEN: Disclosure of transactions in own shares between 17/10/2016 and 21/10/2016 (Businesswire)
10.10.16	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
27.09.16	Ipsen Announces Data Presentations of Cabozantinib (Cabometyx™), Lanreotide (Somatuline® Autogel®) and Telotristat Ethyl* at the European Society for Medical Oncology (ESMO) 2016 Congress (Businesswire)
09.09.16	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
08.08.16	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
01.08.16	Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for Injection for the Treatment of Lower Limb Spasticity in Children Aged Two and Older (Businesswire)
22.07.16	Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy (Businesswire)
11.07.16	David Meek appointed as Chief Executive Officer of Ipsen (Businesswire)
08.07.16	Half-Year IPSEN Liquidity Contract Statement Entered into with NATIXIS (Businesswire)
08.07.16	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
27.06.16	Ipsen initiates a new share buy-back program to cover its free performance share allocation plan (Businesswire)
09.06.16	Ipsen Successfully Issues Inaugural €300 Million 7-Year Notes (Businesswire)
07.06.16	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
06.06.16	The Ipsen Group Launches an Employee Shareholding Plan (Businesswire)
31.05.16	Combined Shareholders’ Meeting of IPSEN S.A. held on 31 May 2016 (Businesswire)
27.05.16	IPSEN: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to the Approval of the Combined Shareholders’ Meeting to Be Held on 31 May 2016 (Businesswire)
10.05.16	Ipsen: Combined Shareholders’ Meeting of 31 May 2016 (Businesswire)
10.05.16	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	536.40	1.02 %	K V
Part Grp Hldg	1’257.00	0.48 %	K V
Roche Hldg G	252.40	0.40 %	K V
Novartis	92.17	0.26 %	K V
Alcon	77.80	0.23 %	K V
CieFinRichemont	121.70	-0.53 %	K V
ABB	49.25	-0.59 %	K V
UBS Group	27.52	-0.86 %	K V
Sika	226.20	-1.05 %	K V
Logitech Intl	70.50	-2.06 %	K V